palmitoylethanolamide.com.au
HomeResearchGomez-Boronat 2019

First evidence on the role of palmitoylethanolamide in energy homeostasis in fish

Gomez-Boronat M, Isorna E, Conde-Sieira M, Delgado MJ, Soengas JL, de Pedro N. Horm Behav. 2020 Jan;117:104609.

Laboratory studyOther animals

Design
Laboratory study
Subjects
Goldfish (Carassius auratus), given acute or chronic intraperitoneal PEA treatment
Dose used in the study
PEA, 20 micrograms/g body weight, intraperitoneal
Duration
Acute (single dose, measured 6-8 hours later) and chronic treatment periods
What was measured
Food intake, locomotor activity, glucose and lipid metabolism, and hepatic transcription factor and clock gene expression.

What the authors reported

Acute PEA reduced food intake at 6 and 8 hours after injection, linked with increased hepatic leptin and reduced hypothalamic NPY expression. Chronic PEA reduced weight gain, growth rate and locomotor activity, raised hepatic glycolytic and lipogenic (fatty acid synthase) activity, and altered REV-ERBalpha and BMAL1 clock gene expression.

Limits of this study

A laboratory fish study; it cannot show effect in mammals or people. Funding and conflicts not stated in the abstract.

Source

PubMed 31647920 · doi:10.1016/j.yhbeh.2019.104609

Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.